Therapeutics Development NOFOs
- RFA-OD-24-014: Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)
- RFA-DA-25-028: Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional)
- PAR-24-064: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
- RFA-DA-25-058: Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3)
- PAR-22-200: Development of medications to prevent and treat opioids/psychostimulant use disorders and overdose (UG3/UH3)
- PAR-22-202: Grand opportunity in medications development to treat substance use disorders (U01)
- PAR-22-182: Behavioral & integrative treatment development program (R01)
- PAR-22-183: Behavioral & integrative treatment development program (R34)
- PAR-21-183: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3)
- PAR-20-279 Device-Based Treatments for Substance Use Disorders (UG3/UH3)